Solid Phase Immunoassay for the Detection of Anticardiolipin Antibodies.
Solid Phase Immunoassay for the Detection of Anticardiolipin Antibodies.
复制标题
DOI：
10.1007/978-1-4939-7196-1_16
复制
发表时间：
2017
影响因子：
--
通讯作者：
R. Willis;E. Papalardo;E. Nigel Harris
中科院分区：
文献类型：
--
作者：
R. Willis;E. Papalardo;E. Nigel Harris
抗心磷脂（aCL）测试首次开发于20世纪80年代，被证明是狼疮抗凝剂检测的一个有价值的补充，用于识别患有后来被称为抗磷脂综合征（APS）的疾病的患者。尽管该试验对APS诊断的特异性相对较差，特别是在低阳性水平下，但由于其高灵敏度和在血清和血浆中测量的能力，并且尽管通常给予APS患者的抗凝剂伴随存在，但它在这些患者的识别和管理中继续发挥重要作用。在本章中，我们概述了生产基本检测组分和进行ACL ELISA的程序，该程序可用于测定人样本中是否存在IgG、IgM和伊加ACL抗体。我们还提供了一般指导原则，将促进ACL ELISA检测的最佳性能。
The anticardiolipin (aCL) test was first developed in the 1980s and proved to be a valuable addition to the lupus anticoagulant assay for identifying patients with a disorder that came to be later known as the antiphospholipid syndrome (APS). Although the test has relatively poor specificity for APS diagnosis, particularly at low positive levels, it has continued to play a major role in the identification and management of these patients because of its high sensitivity and ability to be measured in both serum and plasma, and despite concomitant presence of anticoagulants normally given to APS patients. In this chapter we outline the procedure for producing essential assay components and for performing the aCL ELISA, which can be used to determine the presence of IgG, IgM and IgA aCL antibodies in human samples. We also provide general guidelines that will facilitate optimal performance of the aCL ELISA assay.